Akari Therapeutics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
AKTX
- Investments
-
2
- Share Price
-
$6.80
- (As of Friday Closing)
Akari Therapeutics General Information
Description
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Contact Information
Website
www.akaritx.comCorporate Office
- 75/76 Wimpole Street
- London W1G 9RT
- England, United Kingdom
Corporate Office
- 75/76 Wimpole Street
- London W1G 9RT
- England, United Kingdom
Akari Therapeutics Timeline
Akari Therapeutics Stock Performance
As of 13-Nov-2026, Akari Therapeutics’s stock price is $6.80. Its current market cap is $15.5M with 2.29M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.80 | $6.51 | $3.02 - $29.32 | $15.5M | 2.29M | 63.7K |
Akari Therapeutics Financials Summary
As of 30-Jun-2026, Akari Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 15,897 | 12,864 | 31,050 | 10,457 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (31,838) | (17,353) | (19,541) | (10,086) |
| Net Income | (30,960) | (17,298) | (19,791) | (10,008) |
| Total Assets | 38,624 | 47,892 | 50,562 | 4,355 |
| Total Debt | 693 | 754 | 3,260 | 0 |
Akari Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akari Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Akari Therapeutics Comparisons
Industry
Financing
Details
Akari Therapeutics Competitors (57)
One of Akari Therapeutics’s 57 competitors is Apellis Pharmaceuticals, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| EpimAb Biotherapeutics | Venture Capital-Backed | Shanghai, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cogent Biosciences | Formerly VC-backed | Waltham, MA |
Akari Therapeutics Patents
Akari Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2010247814-A1 | Lipid-polymer conjugates, their preparation and uses thereof | Active | 11-May-2009 | ||
| AU-2010247814-B2 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | ||
| EP-2429532-A1 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | ||
| EP-2429532-A4 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | ||
| AU-2007320737-A1 | Contact lens compositions | Active | 14-Nov-2006 | A61K9/0048 |
Akari Therapeutics Signals
Akari Therapeutics Acquisitions (2)
Akari Therapeutics’s most recent deal was a Merger/Acquisition with Peak Bio for . The deal was made on 14-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Peak Bio | 14-Nov-2024 | Merger/Acquisition | Drug Discovery | ||
| Celsus Therapeutics | 18-Sep-2015 | Merger/Acquisition | Drug Discovery |
Akari Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Peak Bio | Palo Alto, CA | 2015 |
Akari Therapeutics FAQs
-
When was Akari Therapeutics founded?
Akari Therapeutics was founded in 2004.
-
Where is Akari Therapeutics headquartered?
Akari Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Akari Therapeutics?
Akari Therapeutics has 16 total employees.
-
What industry is Akari Therapeutics in?
Akari Therapeutics’s primary industry is Drug Discovery.
-
Is Akari Therapeutics a private or public company?
Akari Therapeutics is a Public company.
-
What is Akari Therapeutics’s stock symbol?
The ticker symbol for Akari Therapeutics is AKTX.
-
What is the current stock price of Akari Therapeutics?
As of 13-Nov-2026 the stock price of Akari Therapeutics is $6.80.
-
What is the current market cap of Akari Therapeutics?
The current market capitalization of Akari Therapeutics is $15.5M.
-
Who are Akari Therapeutics’s competitors?
Apellis Pharmaceuticals, EpimAb Biotherapeutics, BeOne Medicines, CytomX Therapeutics, and Cogent Biosciences are some of the 57 competitors of Akari Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process